Want to see ADCT full AI Analyst Report?
ADCT Stock Chart & Stats
$1.14
>-$0.01(-0.87%)
At close: 4:00 PM EDT
$1.14
>-$0.01(-0.87%)
Day’s Range― - ―
52-Week Range$0.78 - $4.98
Previous Close$1.19
Volume787.75K
Average Volume (3M)1.36M
Market Cap
$141.18M
Enterprise Value$463.69
Total Cash (Recent Filing)$231.01M
Total Debt (Recent Filing)$116.67M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Aug 11, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding127,191,154
10 Day Avg. Volume777,377
30 Day Avg. Volume1,357,523
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)-2.41
Price to Sales (P/S)5.51
P/FCF Ratio-3.17
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.67Price Target Upside397.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.86
Revenue Forecast (FY)$80.21M
Bulls Say, Bears Say
Bulls Say
Commercial Product MomentumSustained product revenue growth demonstrates that ZYNLONTA has commercial traction in its approved setting. Durable uptake as a single-agent third-line-plus DLBCL therapy supports a recurring revenue base that can scale with label expansion and fund ongoing development if growth persists.
High Gross MarginsVery high product-level gross margins indicate strong unit economics for the ADC platform. Once fixed operating costs are controlled and volumes increase, these margins provide a pathway to sustainable profitability and cash generation, improving long-term financial resilience.
Cost Discipline And Multi-Quarter RunwayManagement reduced adjusted operating expenses and reports cash to fund operations at least into 2028. Structural cost control plus multi-year runway lowers near-term financing pressure and gives time to realize regulatory and lifecycle catalysts without immediate dilution.
Bears Say
Weak Balance SheetNegative shareholders' equity and increasing debt materially constrain financial flexibility. This structural imbalance raises refinancing and covenant risks, increases reliance on external capital, and limits the company's ability to invest opportunistically or absorb adverse clinical or commercial outcomes.
Persistent Cash BurnOperating cash flow and free cash flow have been negative across periods and remain a structural headwind. Continued quarterly cash declines imply dependence on financing or milestones; absent sustained revenue growth or approval-driven uptake, funding needs could force dilution or cutbacks.
Safety And Binary Clinical RiskThe Phase 3 readout, while efficacious, flagged higher serious and Grade 5 events in older patients. These safety signals create lasting regulatory and prescribing risk, may narrow the addressable population, necessitate additional risk-mitigation studies, and limit commercial adoption.
ADC Therapeutics News
ADCT FAQ
What was ADC Therapeutics Ltd’s price range in the past 12 months?
ADC Therapeutics Ltd lowest stock price was $0.78 and its highest was $4.98 in the past 12 months.
What is ADC Therapeutics Ltd’s market cap?
ADC Therapeutics Ltd’s market cap is $141.18M.
When is ADC Therapeutics Ltd’s upcoming earnings report date?
ADC Therapeutics Ltd’s upcoming earnings report date is Aug 11, 2026 which is in 10 days.
How were ADC Therapeutics Ltd’s earnings last quarter?
ADC Therapeutics Ltd released its earnings results on May 04, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.008.
Is ADC Therapeutics Ltd overvalued?
According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued.
Does ADC Therapeutics Ltd pay dividends?
ADC Therapeutics Ltd does not currently pay dividends.
What is ADC Therapeutics Ltd’s EPS estimate?
ADC Therapeutics Ltd’s EPS estimate is -0.22.
How many shares outstanding does ADC Therapeutics Ltd have?
ADC Therapeutics Ltd has 127,191,154 shares outstanding.
What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?
ADC Therapeutics Ltd reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went down -3.916%.
Which hedge fund is a major shareholder of ADC Therapeutics Ltd?
Currently, no hedge funds are holding shares in ADCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ADC Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.67 (397.08% Upside)
$5.67 (397.08% Upside)
Blogger Sentiment
Bullish
ADCT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 22.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.96%
Trailing 12-Months
Company Description
ADC Therapeutics Ltd
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
ADCT Company Deck
ADCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced solid operational and financial execution (revenue growth ~15%, 13% reduction in adjusted operating expenses, improved GAAP and non-GAAP losses, and a cash runway into 2028) with near-term risks tied to clinical outcomes and ongoing cost reallocation (higher COGS and quarter-over-quarter cash decline). Management highlighted multiple upcoming data catalysts (LOTIS-5, LOTIS-7, IITs) that could materially drive future growth if positive, but outcome uncertainty and no expected 2026 revenue upside temper near-term outlook.View all ADCT earnings summariesADCT Stock 12 Month Forecast
Average Price Target
$5.67
▲(397.08% Upside)
Technical Analysis
Cellectis SA
―
Black Diamond Therapeutics
―
Innate Pharma
―
Adagene
―
Xilio Therapeutics
―
Ownership Overview
22.72% Insiders
6.25% Mutual Funds
0.28% Other Institutional Investors
65.83% Public Companies and
Individual Investors